17,261 trials
Uveal Melanoma
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) in Phase 1 — 0; 1; 2; 0 Participants
Epilepsy · Tuberous Sclerosis Complex · Focal Cortical Dysplasia
Primary: Number of Patients With Adverse Events — 0; 0 Participants
Metastatic Melanoma
Primary: Percentage of Participants With Progression-free Survival (PFS) at Week 24 — 13.5; 8.9 percentage of participants
Pigmented Villonodular Synovitis · Tenosynovial Giant Cell Tumor
Primary: The Incidence of Grade 3 and Grade 4 Adverse Events (AEs) and Defined as Dose-limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0 Participants
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Diabetes Mellitus, Type 1 · Nephropathy · Diabetic Nephropathies
Primary: Copeptin Levels — 8.3 pmol/L
Type1diabetes · Type1 Diabetes Mellitus · Diabetic Kidney Disease
Primary: Renal Oxygenation — 22.4; 22.5 s^-1
Hemorrhage · Shock · Wounds and Injuries
Primary: Change in HLA-DR Expression on Monocytes 72 Hours After Drug or Placebo Administration in Patient Groups (0g TXA (Placebo); 2g TXA; 4g TXA)." — 0.503; 0.509; 0.532 fold…
Pulmonary Hypertension
Primary: Change in Mean Pulmonary Artery Pressure (MPAP) — 6.5; 4.3 mmHg
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Cure at Visit 3 (Day 7) — 0; 3 Participants
COVID-19 Pneumonia
Primary: Area Under the Curve From Day 0-28 (AUC0-d28) of Tocilizumab) — 371; 849; 837; 1330 µg/mL*day
ADHD
Primary: Number of High-effort Selections in the Effort-based Decision Making Task — 16.4; 21.35; 20.45; 19.8 Number of high-effort selections
Psoriasis
Primary: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI 90) Response Up to Week 16 - Investigational Treatment Period — 0; 0; 0; 0 Percentage of…
Colorectal Cancer Metastatic
Primary: Overall Response Rate — 0 participants
Lymphoma
Primary: Response Rate — 15; 3; 27; 11 Participants